Adjuvansi u vakcinama registrovanim za primenu kod ljudi
| العنوان: | Adjuvansi u vakcinama registrovanim za primenu kod ljudi |
|---|---|
| المؤلفون: | Brankica Filipić, Zorica Stojić-Vukanić |
| المصدر: | Arhiv za farmaciju Arhiv za farmaciju, Vol 69, Iss 6, Pp 406-419 (2019) |
| بيانات النشر: | Beograd : Savez farmaceutskih udruženja Srbije, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Hepatitis B vaccine, imunogenost, medicine.medical_treatment, Pharmaceutical Science, Monophosphoryl Lipid A, lcsh:RS1-441, immunogenicity, lcsh:Pharmacy and materia medica, 03 medical and health sciences, 0302 clinical medicine, medicine, Pandemrix, AS03, Adjuvants, adjuvansi, vakcine, 030304 developmental biology, Pharmacology, 0303 health sciences, Vaccines, business.industry, Malaria vaccine, vaccines, Virology, Immunogenicity, 3. Good health, Vaccination, adjuvants, Cervarix, business, Adjuvant, 030215 immunology |
| الوصف: | Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response. The term adjuvant is from Latin verb adjuvare which means „to aid”. Adjuvants have been used in vaccines for more than 90 years. The longest adjuvant history belongs to aluminium salts, but novel adjuvants have been introduced in licensed vaccines in last 30 years. These novel adjuvants are AS04, which consists of aluminium hydroxide and Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A and is used in hepatitis B vaccine Fendrix® and HPV vaccine Cervarix®, emulsion based adjuvants which are part of several influenza vaccines-MF59 (Fluad® and Focetria®) and AS03 (Pandemrix®), AS01 liposomal adjuvant which is combination of two distinct immunostimulatory molecules and is component of herpes zoster and malaria vaccine and virosomes included in hepatits A vaccine (Epaxal®) and influenza vaccines (Inflexal® V and Invivac®). Adjuvant development and better insight into their mechanism of action are of great importance in order to replace empirical with rational use of adjuvants, without affecting vaccine safety. Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix®) i hepatitis B virusa (Fendrix®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad®, Focetria® i Pandemrix®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine protiv herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal®) i gripa (Inflexal® V, Invivac®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila. |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75f932c5adfb3716d206625fb65992cf https://farfar.pharmacy.bg.ac.rs/bitstream/id/7644/bitstream_7644.pdf |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....75f932c5adfb3716d206625fb65992cf |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |